The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The safety and pharmacokinetics of oral semaglutide were investigated in two randomised, double-blind, placebo-controlled trials. METHODS: In a single-dose, first-in-human trial, 135 healthy males received oral semaglutide (2-20 mg semaglutide co-formulated with 150-600 mg SNAC) or placebo with SNAC. In a 10-week, once-daily, multiple-dose trial, 84 healthy males received 20 or 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC, and 23 males with type 2 diabetes (T2D) received 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC. RESULTS: Oral semaglutide was safe and well-tolerated in both trials. The majority of adverse events (AEs) were mild, with the most common AEs being gastrointestinal disorders. In the single-dose trial, semaglutide exposure was highest when co-formulated with 300 mg SNAC. In the multiple-dose trial, semaglutide exposure was approximately twofold higher with 40 versus 20 mg oral semaglutide in healthy males, in accordance with dose proportionality, and was similar between healthy males and males with T2D. The half-life of semaglutide was approximately 1 week in all groups. CONCLUSION: The safety profile of oral semaglutide was as expected for the GLP-1 receptor agonist drug class. Oral semaglutide co-formulated with 300 mg SNAC was chosen for further clinical development. The pharmacokinetic results supported that oral semaglutide is suitable for once-daily dosing. CLINICALTRIALS. GOV IDENTIFIERS: NCT01037582, NCT01686945.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Arithmetic mean semaglutide plasma concentration-time profiles after a single dose of oral semaglutide with varying amounts of SNAC in healthy male subjects (single-dose trial). Semaglutide plasma concentrations are expressed in percentage of the maximum mean concentration for a 5 mg oral semaglutide with 300 mg SNAC, or b 10 mg oral semaglutide with 300 mg SNAC (see Sect. 2.4 for further details). For subjects with no measurable semaglutide plasma concentration, concentrations were set to 0. SNAC sodium N -(8-[2hydroxybenzoyl] amino) caprylate Modified from Buckley et al. [5]](https://figures.cochat.ai/paper-figures/da7c5581943543db83f337ad9693c80b/safety-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-the-novel-figure-2.png)
![Fig. 3 Arithmetic mean semaglutide plasma concentration-time profiles after ascending single doses of oral semaglutide with 300 mg SNAC in healthy male subjects (single-dose trial). Semaglutide plasma concentrations are expressed in percentage of the maximum mean concentration for 10 mg oral semaglutide with 300 mg SNAC (see Sect. 2.4 for further details). For subjects with no measurable semaglutide plasma concentration, concentrations were set to 0. SNAC sodium N -(8-[2-hydroxybenzoyl] amino) caprylate](https://figures.cochat.ai/paper-figures/8eed11cf15bb4393a273225e321a096d/safety-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-the-novel-figure-3.png)


![[95% CI] and p value. AUC 0-24 h,semaglutide,SS area under the semaglutide plasma concentration-time curve from 0 to 24 h at steady state, Cmax,semaglutide,SS maximum plasma semaglutide concentration at steady state, T2D type 2 diabetes, CI confidence interval](https://figures.cochat.ai/paper-figures/b9de18cdc291436a873988c754e22b05/safety-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-the-novel-figure-6.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other phase 3 trials, no increase in hypoglycemia risk was observed versus comparator groups, including other GLP-1RAs (18–21, 23, 33–36).”
From Safety of Semaglutide (2021) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Basics and Recent Advances in Peptide and Protein Drug Delivery
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 754
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Self-citationIs the oral route possible for peptide and protein drug delivery?
Morishita, M., & Peppas, N. A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.005 · Cited by 515
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Oral Delivery of Anticoagulant Doses of Heparin
Baughman, R., Kapoor, S. C., Agarwal, R., Kisicki, J. C., Catella-Lawson, F., & FitzGerald, G. A. (1998) · Circulation · doi:10.1161/01.cir.98.16.1610 · Cited by 129
Novel strategies in the oral delivery of antidiabetic peptide drugs – Insulin, GLP 1 and its analogs
Ismail, R., & Csóka, I. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.03.015 · Cited by 116
Castelli, M., Wong, D. F., Friedman, K., & Riley, M. G. I. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.05.088 · Cited by 54
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0458-5 · Cited by 50
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
Tan, X., Cao, X., Zhou, M., Zou, P., & Hu, J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1360274 · Cited by 21
Research works printed but not linked: 1
- Bækdal TA, Borregaard J, Donsmark M, Breitschaft A, Søndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide [abstract]. Diabetes. 2017;66(Suppl 1):A315.
Cited by
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
“The pharmacokinetics of oral semaglutide have been established in healthy subjects and subjects with type 2 diabetes and support once-daily dosing (9).”
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Metadata
- Authors
- Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Bækdal, Tine A.
- ORCID
- Bækdal, Tine A.
- Venue
- Clinical Pharmacokinetics
- Published
- 2018-12-18
- Volume
- 58
- Issue
- 6
- Pages
- 781-791
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2903677519
- Cited by
- 190
- References
- 12
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 26 · 2023: 18 · 2022: 24 · 2021: 26 · 2020: 28 · 2019: 13
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, semaglutide, GLP-1 receptor agonists, SNAC, absorption enhancers, pharmacokinetics, safety, type 2 diabetes, dose proportionality, half-life, gastrointestinal adverse effects
- MeSH terms
- Semaglutide, Administration, Oral, Adolescent, Adult, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Male, Metabolic Clearance Rate, Middle Aged, Area Under Curve, Glucagon-Like Peptide 1, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s40262-018-0728-4
- The paper
- Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A. (2019). Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-018-0728-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.